We could not find any results for:
Make sure your spelling is correct or try broadening your search.
€72 million (above $90 million) in cash at end of June 2013 Important news-flow in Q4 for the two lead programs, TG4010 and Pexa-Vec
€72 million (above $90 million) in cash at end of June 2013 Important news-flow in Q4 for the two lead programs, TG4010 and Pexa-Vec
Conducting additional analyses of data, continuing to advance clinical trials in other cancers Announcing decision on Phase 3 development in HCC in Q4
Regulatory News: Transgene SA (Paris:TNG) (Euronext Paris: TNG), a biopharmaceutical company that develops targeted immunotherapy products to treat major unmet medical needs in cancer...
Prof. Laurence Zitvogel (MD) and Mr Jean-Luc Bélingard were elected to the board at the AGM held on June 19, 2013
Transaction will grow Platine Pharma Services’ business by 50% Transgene’s shareholding in Platine will be reduced to around 30%
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions